ECM
FOLD

Element Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Element Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-664,116
Closed -$3.3M – 38
2016
Q4 		$3.3M Buy
+664,116
New +$4.6M 0.34% 46

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Element Capital Management's FOLD Position: Q1 2017 in Review

Element Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2017, closing a stake of 664,116 shares — an estimated $3.3M sold.

Element Capital Management first reported a position in FOLD in Q4 2016 and held it in 1 quarter. The position peaked at $3.3M in Q4 2016. 134 funds tracked by Wall St. Rank hold FOLD as of Q1 2017.

  • Element Capital Management reported no remaining Amicus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Element Capital Management sold 664,116 Amicus Therapeutics shares in Q1 2017, an estimated $3.3M.
  • Element Capital Management first reported a position in Amicus Therapeutics in Q4 2016 and held it in 1 quarter.
  • Element Capital Management's Amicus Therapeutics position peaked at $3.3M in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2017.

Based on Element Capital Management's 13F filing for Q1 2017, filed 12 May 2017.